Levinson Mitchell E.
Known title: Chief Strategy OfficerCIK: 0001674465
Levinson Mitchell E.'s purchase track record
Levinson Mitchell E. has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/15/2023 | PLSE | $105K | +37.6% | +13.8% | +17.9% |
| 10/7/2022 | PLSE | $70K | +40.8% | +89.5% | +12.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PLSE | ▼ Sell | Other | 1,240 | $14K | 9/24/2024 | View on chart |
| PLSE | ▼ Sell | Other | 322 | $4K | 9/24/2024 | View on chart |
| PLSE | ▼ Sell | Other | 322 | $4K | 9/24/2024 | View on chart |
| PLSE | ▼ Sell | Other | 322 | $4K | 9/24/2024 | View on chart |
| PLSE | ▼ Sell | Other | 3,000 | $33K | 9/24/2024 | View on chart |
| PLSE | ▼ Sell | Other | 322 | — | 7/3/2024 | View on chart |
| PLSE | ▼ Sell | Other | 3,000 | — | 7/3/2024 | View on chart |
| PLSE | ▼ Sell | Other | 322 | — | 7/3/2024 | View on chart |
| PLSE | ▼ Sell | Other | 1,241 | — | 7/3/2024 | View on chart |
| PLSE | ▼ Sell | Other | 322 | — | 7/3/2024 | View on chart |
| PLSE | ▲ Buy | Open Market | 5,000 | $30K | 11/15/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 461 | $3K | 11/15/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 3,800 | $22K | 11/15/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 200 | $1K | 11/15/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 2,300 | $14K | 11/15/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 100 | $594 | 11/15/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 2,400 | $14K | 11/15/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 2,400 | $14K | 11/15/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 1,039 | $6K | 11/15/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 100 | $590 | 11/15/2023 | View on chart |
| PLSE | ▼ Sell | Other | 143 | $293 | 5/25/2023 | View on chart |
| PLSE | ▼ Sell | Other | 143 | $293 | 5/25/2023 | View on chart |
| PLSE | ▼ Sell | Other | 10,935 | $22K | 5/25/2023 | View on chart |
| PLSE | ▼ Sell | Other | 814 | $2K | 5/25/2023 | View on chart |
| PLSE | ▼ Sell | Other | 143 | $293 | 5/25/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 8,810 | $20K | 10/7/2022 | View on chart |
| PLSE | ▲ Buy | Open Market | 4,500 | $10K | 10/7/2022 | View on chart |
| PLSE | ▲ Buy | Open Market | 4,300 | $10K | 10/7/2022 | View on chart |
| PLSE | ▲ Buy | Open Market | 8,770 | $20K | 10/7/2022 | View on chart |
| PLSE | ▲ Buy | Open Market | 4,400 | $10K | 10/7/2022 | View on chart |
| PLSE | ▼ Sell | Other | 814 | — | 6/9/2022 | View on chart |
| PLSE | ▼ Sell | Other | 143 | — | 6/9/2022 | View on chart |
| PLSE | ▼ Sell | Other | 143 | — | 6/9/2022 | View on chart |
| PLSE | ▼ Sell | Other | 143 | — | 6/9/2022 | View on chart |
| PLSE | ▼ Sell | Other | 10,935 | — | 6/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Pulse Biosciences Partners with Clayman Thyroid Center
Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center in Tampa, Florida. Additionally, Oppenheimer raised its price target to $60 and maintained an Outperform rating, citing the importance of the 2027 trial readout for the company's new ablation modality. The stock recently saw a 12.3% rise following the completion of full enrollment for the NANOPULSE-AF trial.
Pulse Biosciences Partners with Clayman Thyroid Center. Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center in Tampa, Florida. Additionally, Oppenheimer raised its price target to $60 and maintained an Outperform rating, citing the importance of the 2027 trial readout for the company's new ablation modality. The stock recently saw a 12.3% rise following the completion of full enrollment for the NANOPULSE-AF trial.